SLC5A2 and cancer: SGLT‐2 inhibitors have emerged as potential metabolic modulators in oncology, with preclinical data suggesting that they reduce intracellular glucose availability, induce mitochondrial dysfunction, and suppress inflammation, thereby impairing cancer cell survival (Figure 3).